NCT03625388View on ClinicalTrials.gov

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

July 22, 2023

Study Completion Date

July 22, 2023

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

Dasatinib

Film coated tablet contains dasatinib monohydrate

Trial Locations (5)

1006

Aziza Othmana Hospital, Tunis

11941

King Hussein Cancer Center (KHCC), Amman

11942

Jordan University Hospital (JUH), Amman

Unknown

American University of Beirut Medical Center (AUBMC), Beirut

The King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh

Sponsors
All Listed Sponsors
lead

Hikma Pharmaceuticals LLC

INDUSTRY